Injectable paromomycin for Visceral leishmaniasis in India.

By S. Sundar, T. K. Jha, C. P. Thakur, P. Sinha, S. Bhattacharya. 2007

437 citations recorded by the source corpus.

Subfields: Epidemiology, Health, Toxicology and Mutagenesis, Public Health, Environmental and Occupational Health

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. S. Sundar
2. K. Krause
3. Timothy R. Kane
4. L. Connolly
5. A. Serio

In Public Health, Environmental and Occupational Health

1. S. Sundar
2. F. Chappuis
3. J. Alvar
4. L. Gradoni

Citations in the corpus

• SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery (2013, neutral): “comparison to de novo design[4-11].”
• The Relationship between Leishmaniasis and AIDS: the Second 10 Years (2008, methodology): “Paromomycin sulfate was recently licensed for the treatment of VL on the basis of a large phase III trial, where it was shown to be as effective as AMB and was very well tolerated; the main side effects were a reversible elevation of liver enzymes, in approximately 1% of patients, and pain at the in”
• Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? (2007, background): “8% of patients showed a significant increase (>fivefold) in hepatic transaminase”
• Aminoglycosides: An Overview. (2016, background): “A SENTRY surveillance study from the Asia-Pacific region (2007–2008) detected genes encoding RMTs in 6.9% (China), 10.5% (India), 1.5% (Hong Kong), 6.1% (Korea), and 5.0% (Taiwan) of Enterobacteriaceae isolates (Bell et al. 2010).”